Abstract 2914
Background
Acute lymphoblastic leukaemia (ALL) is associated with high survival rates in paediatrics and young adults and less favourable outcomes in older adults. Clinical trials (CTs) studying survival-based endpoints in ALL lead to significantly prolonged trial durations, resulting in delays to medicines access. Biomarkers in ALL have been correlated with longer-term outcomes, potentially accelerating the clinical development of novel treatments. The aim of this study was to characterise efficacy measures investigated in ALL CTs conducted in the European Union (EU)/Economic Area (EEA).
Methods
Interventional Phase II to Phase IV ALL CTs registered in the EU Clinical Trials Register over an 11-year period (2007-2017) were identified. Therapeutic CTs reporting efficacy data in the English language for investigational medicinal products of chemical, biological and biotechnological origin were included in the study. A protocol design or age filter was not applied to avoid limiting the scope of outcomes identified. Primary and secondary efficacy endpoints were extracted from the selected CTs and categorised according to type of measurement. A data mining process was performed to detect trends in outcomes studied.
Results
The data set comprised 68 CTs representing about 20,000 patients. The majority of trials (69%, n = 47) recruited patients from the adult population (18-64 years) and conducted only Phase II studies (62%, n = 42). Twenty-three unique efficacy endpoints were identified and stratified into the clusters of survival (n = 4), time-to-event (n = 3), response rates and biomarkers (n = 11) and other (n = 5). Fifty-three per cent (n = 36) of the trials reported 4-10 outcomes, with a mean of 4 outcomes per CT (range 1-10). The principal endpoints evaluated in CTs consisted of overall survival (CTs: 63%, n = 43), minimal residual disease (CTs: 50%, n = 34), event-free survival (CTs: 40%, n = 27) and disease-free survival (CTs: 40%, n = 27).
Conclusions
The high uptake of minimal residual disease as an efficacy parameter in ALL CTs is in line with reported findings confirming the prognostic value of this marker on clinical outcomes. Heterogeneity in the selection of efficacy endpoints was observed which warrants future work on the standardisation of efficacy outcomes in ALL CTs.
Clinical trial identification
Editorial acknowledgement
The Malta Medicines Authority. The Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta.
Legal entity responsible for the study
Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta.
Funding
Government of Malta, Endeavour Scholarship Scheme 2017.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract